Sign inJoin waitlistJoin the waitlist

Joerg Herrmann

Director, Cardio Oncology Clinic, Division of Preventive Cardiology, Department of Cardiovascular Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · ·

History

Division of Critical Care Cardiology Department · Mayo Clinic College of Medicine and Science
Present
Division of Ischemic Heart Disease and Critical Care · Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

2004–2005
Cardiovascular Disease
Mayo Clinic College of Medicine and Science
2001–2004
Internal Medicine
Mayo Clinic College of Medicine and Science
1998–2001
Internal Medicine University Clinic
1997–1998
Faculty of Medicine at Ruhr-Universität Bochum
1993–1997

Research

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology…
European Heart Journal · 2022 · 2,510 citations
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Annals of Oncology · 2020 · 761 citations
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the…
European Journal of Heart Failure · 2020 · 646 citations

AL
Amir Lerman
82 papers
Lilach Lerman
48 papers
Anita Deswal
18 papers
Cezar Iliescu
18 papers
Eric Yang
18 papers
Hector Villarraga
18 papers
Kathryn Ruddy
18 papers
DL
Daniel Lenihan
16 papers
Susan Dent
15 papers
Ana Barac
14 papers
Martin Rodriguez-Porcel
13 papers
DH
David Holmes
12 papers

Grants

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial
National Cancer Institute · R01
Contact PI · $4.3M · Mayo Clinic Rochester
2019–2027
The Pathophysiological Role of the Immunoproteasome in Atherosclerosis
National Heart, Lung, and Blood Institute · K08
Contact PI · $750.4K · Mayo Clinic Rochester
2014–2018

Clinical trials

Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
Principal investigator · Recruiting · Phase 1, Phase 2
Mayo Clinic
2026–2030
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
Principal investigator · Recruiting
Mayo Clinic
2025–2029
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Principal investigator · Recruiting
Mayo Clinic
2024–2026
Cancer Survivor Cardiomyopathy Detection
Principal investigator · Terminated
Mayo Clinic
2022–2026